Functional variants of the 5-methyltetrahydrofolate-homocysteine methyltransferase gene significantly increase susceptibility to prostate cancer: Results from an ethnic Han Chinese population

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Qu, Yuan Yuan ^a,b   Zhou, Shu Xian ^b,c   Zhang, Xuan ^c   Zhao, Rui ^b,c   Gu, Cheng Yuan ^a,b   Chang, Kun ^a,b   Yang, Xiao Qun ^a,b   Gan, Hua Lei ^a,b   Dai, Bo ^a,b   Zhang, Hai Liang ^a,b   Shi, Guo Hai ^a,b   Zhu, Yao ^a,b   Ye, Ding Wei ^a,b   Zhao, Jian Yuan ^c  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLTETRAHYDROFOLATE HOMOCYSTEINE METHYLTRANSFERASE;

AGED; CASE CONTROL STUDY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PROSTATE TUMOR; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

5-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE S-METHYLTRANSFERASE; AGED; CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84994384386     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep36264     Document Type: Article

References (42)

1. Ferlay, J. et al. Estimates of the cancer incidence and mortality in Europe in 2006. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 18, 581-592, doi: 10.1093/annonc/mdl498 (2007).
2. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2015. CA: a cancer journal for clinicians 65, 5-29, doi: 10.3322/caac.21254 (2015).
3. Qu, Y. et al. Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer. Scientific reports 5, 7654, doi: 10.1038/srep07654 (2015).
4. Collin, S. M. et al. Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysis. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 18, 2528-2539, doi: 10.1158/1055-9965.EPI-09-0223 (2009).
5. Kimura, F. et al. Methyl group metabolism gene polymorphisms and susceptibility to prostatic carcinoma. The Prostate 45, 225-231 (2000).
6. Marchal, C. et al. Association between polymorphisms of folate-metabolizing enzymes and risk of prostate cancer. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 34, 805-810, doi: 10.1016/j.ejso.2007.09.008 (2008).
7. Nelson, W. G., De Marzo, A. M. & Isaacs, W. B. Prostate cancer. The New England journal of medicine 349, 366-381, doi: 10.1056/NEJMra021562 (2003).
8. Zingg, J. M. & Jones, P. A. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis 18, 869-882 (1997).
9. Wang, Y. et al. Roles of Distal and Genic Methylation in the Development of Prostate Tumorigenesis Revealed by Genome-wide DNA Methylation Analysis. Scientific reports 6, 22051, doi: 10.1038/srep22051 (2016).
10. Kim, J. H. et al. Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome research 21, 1028-1041, doi: 10.1101/gr.119347.110 (2011).
11. Eden, A., Gaudet, F., Waghmare, A. & Jaenisch, R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300, 455, doi: 10.1126/science.1083557 (2003).
12. Yegnasubramanian, S. et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer research 68, 8954-8967, doi: 10.1158/0008-5472.CAN-07-6088 (2008).
13. Bistulfi, G., Vandette, E., Matsui, S. & Smiraglia, D. J. Mild folate deficiency induces genetic and epigenetic instability and phenotype changes in prostate cancer cells. BMC biology 8, 6, doi: 10.1186/1741-7007-8-6 (2010).
14. Hazra, A. et al. Germline polymorphisms in the one-carbon metabolism pathway and DNA methylation in colorectal cancer. Cancer causes & control: CCC 21, 331-345, doi: 10.1007/s10552-009-9464-2 (2010).
15. Song, M. A. et al. Genetic variation in one-carbon metabolism in relation to genome-wide DNA methylation in breast tissue from heathy women. Carcinogenesis, doi: 10.1093/carcin/bgw030 (2016).
16. Friso, S. et al. The MTHFR 1298A > C polymorphism and genomic DNA methylation in human lymphocytes. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 14, 938-943, doi: 10.1158/1055-9965.EPI-04-0601 (2005).
17. Deroo, L. A. et al. Global DNA methylation and one-carbon metabolism gene polymorphisms and the risk of breast cancer in the Sister Study. Carcinogenesis 35, 333-338, doi: 10.1093/carcin/bgt342 (2014).
18. Zhao, J. Y. et al. Genetic variants reducing MTR gene expression increase the risk of congenital heart disease in Han Chinese populations. European heart journal 35, 733-742, doi: 10.1093/eurheartj/eht221 (2014).
19. Zhao, J. Y. et al. Functional variant in methionine synthase reductase intron-1 significantly increases the risk of congenital heart disease in the Han Chinese population. Circulation 125, 482-490, doi: 10.1161/CIRCULATIONAHA.111.050245 (2012).
20. Zhao, J. Y. et al. A functional variant in the cystathionine beta-synthase gene promoter significantly reduces congenital heart disease susceptibility in a Han Chinese population. Cell research, doi: 10.1038/cr.2012.135 (2012).
21. de Vogel, S. et al. Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 18, 3086-3096, doi: 10.1158/1055-9965.EPI-09-0289 (2009).
22. de Cassia Carvalho Barbosa, R., da Costa, D. M., Cordeiro, D. E., Vieira, A. P. & Rabenhorst, S. H. Interaction of MTHFR C677T and A1298C, and MTR A2756G gene polymorphisms in breast cancer risk in a population in Northeast Brazil. Anticancer research 32, 4805-4811 (2012).
23. Matsuo, K. et al. Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma. Blood 97, 3205-3209 (2001).
24. He, J. et al. No association between MTR rs1805087 A > G polymorphism and non-Hodgkin lymphoma susceptibility: evidence from 11 486 subjects. Leukemia & lymphoma 56, 763-767, doi: 10.3109/10428194.2014.935370 (2015).
25. Zhou, D., Mei, Q., Luo, H., Tang, B. & Yu, P. The polymorphisms in methylenetetrahydrofolate reductase, methionine synthase, methionine synthase reductase, and the risk of colorectal cancer. International journal of biological sciences 8, 819-830, doi: 10.7150/ijbs.4462 (2012).
26. Caudill, M. A. et al. Intracellular S-adenosylhomocysteine concentrations predict global DNA hypomethylation in tissues of methyldeficient cystathionine beta-synthase heterozygous mice. The Journal of nutrition 131, 2811-2818 (2001).
27. Fryer, A. A. et al. LINE-1 DNA methylation is inversely correlated with cord plasma homocysteine in man: a preliminary study. Epigenetics 4, 394-398 (2009).
28. Chen, N. C. et al. Regulation of homocysteine metabolism and methylation in human and mouse tissues. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 24, 2804-2817, doi: 10.1096/fj.09-143651 (2010).
29. Stam, F. et al. Homocysteine clearance and methylation flux rates in health and end-stage renal disease: association with S-adenosylhomocysteine. American journal of physiology. Renal physiology 287, F215-F223, doi: 10.1152/ajprenal.00376.2003 (2004).
30. Hillemacher, T., Frieling, H., Muschler, M. A. & Bleich, S. Homocysteine and epigenetic DNA methylation: a biological model for depression? The American journal of psychiatry 164, 1610, doi: 10.1176/appi.ajp.2007.07060881 (2007).
31. Jackson, M. D. et al. Complex interaction between serum folate levels and genetic polymorphisms in folate pathway genes: biomarkers of prostate cancer aggressiveness. Genes & nutrition 8, 199-207, doi: 10.1007/s12263-012-0321-7 (2013).
32. Zelic, R. et al. Global DNA hypomethylation in prostate cancer development and progression: a systematic review. Prostate cancer and prostatic diseases 18, 1-12, doi: 10.1038/pcan.2014.45 (2015).
33. Jones, P. A. Overview of cancer epigenetics. Seminars in hematology 42, S3-S8 (2005).
34. Brothman, A. R. et al. Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome? Cancer genetics and cytogenetics 156, 31-36, doi: 10.1016/j.cancergencyto.2004.04.004 (2005).
35. Zhang, L. et al. One-carbon metabolism pathway gene variants and risk of clear cell renal cell carcinoma in a Chinese population. PloS one 8, e81129, doi: 10.1371/journal.pone.0081129 (2013).
36. Gallegos-Arreola, M. P. et al. The association between the 844ins68 polymorphism in the CBS gene and breast cancer. Archives of medical science: AMS 10, 1214-1224, doi: 10.5114/aoms.2014.47830 (2014).
37. Galbiatti, A. L. et al. The association between CBS 844ins68 polymorphism and head and neck squamous cell carcinoma risk - a case-control analysis. Archives of medical science: AMS 6, 772-779, doi: 10.5114/aoms.2010.17094 (2010).
38. Weiner, A. S. et al. Polymorphisms in the folate-metabolizing genes MTR, MTRR, and CBS and breast cancer risk. Cancer epidemiology 36, e95-e100, doi: 10.1016/j.canep.2011.11.010 (2012).
39. Zhang, H. et al. Genetic variations in the one-carbon metabolism pathway genes and susceptibility to hepatocellular carcinoma risk: a case-control study. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 36, 997-1002, doi: 10.1007/s13277-014-2725-z (2015).
40. Cheng, L., Montironi, R., Bostwick, D. G., Lopez-Beltran, A. & Berney, D. M. Staging of prostate cancer. Histopathology 60, 87-117, doi: 10.1111/j.1365-2559.2011.04025.x (2012).
41. Sun, X., Tan, Y., Yang, Z., Li, S. & Hoffman, R. M. A rapid HPLC method for the measurement of ultra-low plasma methionine concentrations applicable to methionine depletion therapy. Anticancer research 25, 59-62 (2005).
42. Consultation, W. H. O. E. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363, 157-163, doi: 10.1016/S0140-6736(03)15268-3 (2004).